Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18642056 | 1.00 | PPM1D (0.36) | PPM1D | |
| SCHEMBL21876157 | 1.00 | PPM1D (0.36) | PPM1D | |
| SCHEMBL20428523 | 0.84 | PPM1D (0.34) | PPM1D | |
| SCHEMBL27035499 | 0.84 | PPM1D (0.37) | PPM1D | |
| SCHEMBL15236729 | 0.84 | PPM1D (0.34) | PPM1D | |
| SCHEMBL600840 | 0.84 | PPM1D (0.37) | PPM1D | |
| SCHEMBL1526837 | 0.84 | PPM1D (0.37) | PPM1D | |
| SCHEMBL20993359 | 0.83 | PPM1D (0.32) | PPM1D | |
| SCHEMBL15115983 | 0.81 | SMN1; SMN2 (0.41) | PPM1D | |
| SCHEMBL3580736 | 0.81 | SMN1; SMN2 (0.41) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| EP-3852748-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-3609888-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596041-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4596543-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-113056271-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-110637011-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2020061118-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3609888-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110637011-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-110637015-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | disclosed |
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2018-10-04 | — | — | US | disclosed |
| WO-2018170173-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018170166-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018170182-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180251429-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251429-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PPM1D 3604/4885 |
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | PPM1D 3604/4885 |
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PPM1D 3604/4885 |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PPM1D 3604/4885 |
| US-20180282263-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PPM1D 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.